

INFINITY - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!

<https://marketpublishers.com/r/I3942F021D6EN.html>

Date: February 2013

Pages: 8

Price: US\$ 140.00 (Single User License)

ID: I3942F021D6EN

Abstracts

Regaining WW rights of IPI-145 (PI3K-delta, gamma isoform inhibitor, PhI/II, hematological malignancies, inflammation) from Takeda and targeting both hematologic malignancies and inflammation indication has sparked interest in Infinity Pharma (INFI). Despite limited clinical data in hand, PC and in vitro study demonstrates competitive advantages vs. drugs in pipeline hence the licensing/acquisition chances are bright. Based on PC data, IPI-145 is more potent than Gilead's PI3K inhibitor Idelalisib (GS1101, PhIII). In a PhI study, IPI-145 has shown rapid onset of clinical activity in CLL/SLL as mono therapy. IPI-145's Potential not dimmed even as a 3rd/4th For more details, please read our report released on 13th February 2013 on INFI titled "IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!"

I would like to order

Product name: INFINITY - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!

Product link: <https://marketpublishers.com/r/I3942F021D6EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I3942F021D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970